Fungal Infections Diagnosis Market by Type, Diagnostic Method, End-User

Description

List of Tables

[194 Pages Report] The Fungal Infections Diagnosis Market size was estimated at USD 2.09 billion in 2023 and expected to reach USD 2.23 billion in 2024, at a CAGR 6.96% to reach USD 3.35 billion by 2030.

Global Fungal Infections Diagnosis Market

KEY MARKET STATISTICS
Base Year [2023]	USD 2.09 billion
Estimated Year [2024]	USD 2.23 billion
Forecast Year [2030]	USD 3.35 billion
CAGR (%)	6.96%

Fungal Infections Diagnosis Market - IMG1

Fungal infections, or mycosis, refer to infections or diseases caused by a fungus species (yeast or mold). Fungal infections are most commonly observed on the skin or nails, but fungi can also cause infections in the mouth, throat, lungs, and urinary tract. Fungal infections come in different forms, such as ringworm athlete's foot, toenail fungus, yeast infections, and jock itch. Diagnosis of fungal infection primarily relies on methodologies such as microscopic examination of clinical samples, histopathology, culture, X-rays, MRI, or CT imaging. The rising incidences of fungal infections across the world have led to a surge in demand for effective disease detection technologies. Furthermore, government initiatives promoting awareness of fungal infection management and efforts to expand access to healthcare facilities have led to rising adoption of fungal infection diagnosis. However, the complexity of molecular and genetic fungal infection diagnosis and the lack of skilled medical and clinical personnel impeded the growth of fungal infection diagnosis solutions. Additionally, inaccurate or inconsistent diagnosis results and stringent regulations pertaining to product approval also pose challenges for fungal infection diagnosis devices, solutions, and services. However, major players are rapidly expanding investments in R&D initiatives to improve the capabilities and accuracy of diagnosis technologies. Advances in imaging technologies enhanced digital solutions for remote diagnosis and the introduction of artificial intelligence in rapid diagnostic techniques present opportunities for growth.

Regional Insights

The Americas, specifically the US and Canada, present a mature region for fungal infections diagnostic tools, attributable to the increased public consciousness about fungal infections. Americas is characterized by the presence of robust research institutions and medical infrastructure, contributing to the timely and accurate diagnosis of various fungal infections. The technological advancements in diagnostic techniques, including PCR and next-generation sequencing, have accelerated the diagnosis process, improved accuracy, and reduced the potential risk of fatality in the Americas region. In Europe, the spread of fungal infections shows a significant increase, mostly attributed to the elderly population and those with immunosuppressive conditions. There is a rising demand for effective diagnostic tools driven by increased awareness about fungal infections. European region exhibits a rise in travel and migration, which contributes to the introduction and spread of various fungal pathogens. Medical practitioners, therefore, adopt innovative fungal infection diagnostics to manage the potential outbreaks in this high-risk environment effectively. Significant investments in R&D and a growing number of start-ups characterize this region. Asia-Pacific (APAC) region is witnessing an upsurge in the incidence of fungal infections, primarily due to escalating population density and climatic conditions that favor fungal growth. The APAC region, chiefly China, Japan, and India, shows immense potential due to escalating healthcare expenditure and a surge in patient awareness.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Fungal Infections Diagnosis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Fungal Infections Diagnosis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Fungal Infections Diagnosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alexion Pharmaceuticals, Inc., Amgen Inc., Associates of Cape COD, Inc. by Seikagaku Group company, Astellas Pharma Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMerieux SA, Bruker Corporation, Danaher Corporation, Eli Lilly and Company, ELITech Group, Eurofins Viracor, LLC, F. Hoffmann-La Roche AG, Hologic, Inc., Immununexpress Inc., IMMY, InBios International, Inc., Laboratory Corporation of America Holdings, Merck KGaA, Norgen Biotek Corp., PerkinElmer, Inc., Polysciences, Inc., Qiagen N.V., Siemens Healthineers, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Fungal Infections Diagnosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Endemic Fungal Infections
- Opportunistic Fungal Infections
- Subcutaneous Fungal Infections
- Superficial Fungal Infections
- Systemic Fungal Infections
Diagnostic Method
- Antigen Testing
- Dermatological Examination
- Histopathology
- Microbiological Culture
- Molecular Diagnostics
- Serology
End-User
- Hospitals
- Point-of-Care Settings
- Research Institutions
- Specialty Clinics
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Fungal Infections Diagnosis Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Fungal Infections Diagnosis Market?

3. What are the technology trends and regulatory frameworks in the Fungal Infections Diagnosis Market?

4. What is the market share of the leading vendors in the Fungal Infections Diagnosis Market?

5. Which modes and strategic moves are suitable for entering the Fungal Infections Diagnosis Market?

Product Code: MRR-346757DFA1EA

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Fungal Infections Diagnosis Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of fungal infections and need for effective diagnosis methods
  - 5.1.1.2. Government initiatives promoting awareness of fungal infection management
  - 5.1.1.3. Favorable approvals for fungal infection test series
- 5.1.2. Restraints
  - 5.1.2.1. Complexity of molecular and genetic fungal infection diagnosis
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in molecular and point-of-care diagnosis technologies
  - 5.1.3.2. Potential of teledermatology in fungal infection detection and diagnosis
- 5.1.4. Challenges
  - 5.1.4.1. Limitations associated with the inaccuracy of the diagnostic methods
5.2. Market Segmentation Analysis
- 5.2.1. Type: Growing incidences of opportunistic fungal infections due to weakened immune system in patients
- 5.2.2. Diagnostic Method: Advancements in cellular and molecular biology leading to the adoption of molecular diagnostics for infection detection
- 5.2.3. End-user: Expanding healthcare expenditure leading to growth and significance of hospitals for fungal infection diagnosis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Fungal Infections Diagnosis Market, by Type

6.1. Introduction
6.2. Endemic Fungal Infections
6.3. Opportunistic Fungal Infections
6.4. Subcutaneous Fungal Infections
6.5. Superficial Fungal Infections
6.6. Systemic Fungal Infections

7. Fungal Infections Diagnosis Market, by Diagnostic Method

7.1. Introduction
7.2. Antigen Testing
7.3. Dermatological Examination
7.4. Histopathology
7.5. Microbiological Culture
7.6. Molecular Diagnostics
7.7. Serology

8. Fungal Infections Diagnosis Market, by End-User

8.1. Introduction
8.2. Hospitals
8.3. Point-of-Care Settings
8.4. Research Institutions
8.5. Specialty Clinics

9. Americas Fungal Infections Diagnosis Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Fungal Infections Diagnosis Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Fungal Infections Diagnosis Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
- 12.3.1. New Product Launch & Enhancement
  - 12.3.1.1. University of Minnesota Research Team Successfully Tests New Antifungal Therapy For Fungal Meningitis
  - 12.3.1.2. Applied BioCode Announces the Launch of the Fungal Panel Assay for Research Use
  - 12.3.1.3. University of Arizona Researchers to Help Track Deadly Fungus in Arizona Wastewater

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. Abbott Laboratories
- 13.1.2. Alexion Pharmaceuticals, Inc.
- 13.1.3. Amgen Inc.
- 13.1.4. Associates of Cape COD, Inc. by Seikagaku Group company
- 13.1.5. Astellas Pharma Inc.
- 13.1.6. Becton, Dickinson and Company
- 13.1.7. Bio-Rad Laboratories, Inc.
- 13.1.8. BioMerieux SA
- 13.1.9. Bruker Corporation
- 13.1.10. Danaher Corporation
- 13.1.11. Eli Lilly and Company
- 13.1.12. ELITech Group
- 13.1.13. Eurofins Viracor, LLC
- 13.1.14. F. Hoffmann-La Roche AG
- 13.1.15. Hologic, Inc.
- 13.1.16. Immununexpress Inc.
- 13.1.17. IMMY
- 13.1.18. InBios International, Inc.
- 13.1.19. Laboratory Corporation of America Holdings
- 13.1.20. Merck KGaA
- 13.1.21. Norgen Biotek Corp.
- 13.1.22. PerkinElmer, Inc.
- 13.1.23. Polysciences, Inc.
- 13.1.24. Qiagen N.V.
- 13.1.25. Siemens Healthineers
- 13.1.26. Takeda Pharmaceutical Company Limited
- 13.1.27. Thermo Fisher Scientific Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing